Eleven Biotherapeutics Reports Signing of Exclusive License Agreement, Will Receive $7.5M Upfront and Potentially $262.5M Based Off Milestone Payments; License To Roche Covers IL-6 Antagonist Antibody Tech; IND Submission Announced Today For EBI-031